Skip to main content
38°
Rain
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Betterlife Pharma Inc
(OP:
BETRF
)
0.0867
UNCHANGED
Streaming Delayed Price
Updated: 10:35 AM EST, Feb 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Betterlife Pharma Inc
< Previous
1
2
Next >
USPTO Grants BetterLife’s BETR-001 Composition of Matter Patent
January 14, 2025
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Favorable Outcome in New York Legal Claims
December 09, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Obtains Favourable Cardiac Safety Data for BETR-001
November 25, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001
October 23, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Fully Subscribed Private Placement Financing
August 29, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Closing of a Private Placement
July 02, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent
August 27, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Closing of a Private Placement
June 14, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife To Present BETR-001 Preclinical Data at the 2024 Conference of the Federation of European Neuroscience Societies (FENS) in Vienna, Austria
June 26, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
May 14, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Intent to Complete Private Placement of Units
May 03, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Advances BETR-001 IND-enabling Studies
May 01, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 11, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
January 02, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001
April 03, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Closing of a Private Placement
December 18, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
March 04, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Extension of Warrants
November 30, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives
November 15, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Pharma to Host Investors Update Call on September 18, 2023
September 14, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
September 12, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives
June 27, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement
September 05, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Continues Progress on BETR-001 IND-Enabling Studies
June 08, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement
July 13, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
April 20, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
June 22, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
Promise of BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article
March 22, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California
April 25, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
March 29, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
